PAP
PTHS

Persistent Asset Partners’s Pelthos Therapeutics PTHS Stock Holding History

Persistent Asset Partners’s Portfolio PTHS Stock Details PTHS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$170K Hold
6,007
– – 0.05% 235
2026
Q1 		$126K Hold
6,007
– – 0.05% 229
2025
Q4 		$186K Buy
6,007
+3,604
+150% +$104K 0.08% 219
2025
Q3 		$67.3K Buy
+2,403
New +$58.3K 0.05% 170

Other funds holding PTHS

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
DMKJ
David M. Knott Jr $189M AUM 67.72% 1-Year Est. Return

Persistent Asset Partners's PTHS Position: Q2 2026 in Review

Persistent Asset Partners held its Pelthos Therapeutics (PTHS) position steady in Q2 2026 at 6,007 shares worth $170K. The position accounts for 0.05% of the portfolio, ranked #235.

Persistent Asset Partners first reported a position in PTHS in Q3 2025 and has held it in 4 quarters since. The position peaked at $186K in Q4 2025. 24 funds tracked by Wall St. Rank hold PTHS as of Q2 2026.

  • Persistent Asset Partners held 6,007 shares of Pelthos Therapeutics worth $170K as of Q2 2026.
  • Persistent Asset Partners left its Pelthos Therapeutics share count unchanged in Q2 2026.
  • Pelthos Therapeutics made up 0.05% of Persistent Asset Partners's portfolio in Q2 2026, its #235 holding.
  • Persistent Asset Partners first reported a position in Pelthos Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Persistent Asset Partners's Pelthos Therapeutics position peaked at $186K in Q4 2025.
  • 24 funds tracked by Wall St. Rank held Pelthos Therapeutics as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.